{
  "query": "What drugs target the ACVR1 pathway in fibrodysplasia ossificans progressiva (FOP)?",
  "disease": {
    "id": "MONDO:0007606",
    "name": "fibrodysplasia ossificans progressiva",
    "type": "Disease"
  },
  "nodes": [
    {
      "id": "HGNC:171",
      "type": "Gene",
      "label": "ACVR1",
      "properties": {
        "symbol": "ACVR1",
        "name": "activin A receptor type 1",
        "ensembl": "ENSG00000115170",
        "uniprot": "Q04771",
        "entrez": "90",
        "alias_symbols": ["SKR1", "ALK2", "ACVR1A"],
        "location": "2q24.1"
      }
    },
    {
      "id": "UniProtKB:Q04771",
      "type": "Protein",
      "label": "ACVR1",
      "properties": {
        "name": "Activin receptor type-1",
        "function": "Bone morphogenetic protein (BMP) type I receptor that forms heterotetrameric complexes with type II receptors AMHR2, ACVR2A or ACVR2B. Upon ligand binding (BMP7, GDF2/BMP9), type II receptors transphosphorylate ACVR1, which then phosphorylates SMAD1/5/8 proteins. Can activate non-canonical p38 MAPK pathway.",
        "organism": "Homo sapiens"
      }
    },
    {
      "id": "HGNC:171",
      "type": "Gene",
      "label": "ACVR2A",
      "properties": {
        "symbol": "ACVR2A",
        "name": "activin A receptor type 2A",
        "ensembl": "ENSG00000121989"
      }
    },
    {
      "id": "HGNC:171",
      "type": "Gene",
      "label": "ACVR2B",
      "properties": {
        "symbol": "ACVR2B"
      }
    },
    {
      "id": "STRING:9606.ENSP00000405004",
      "type": "Protein",
      "label": "ACVR1",
      "properties": {
        "preferred_name": "ACVR1",
        "taxon_id": 9606
      }
    },
    {
      "id": "CHEMBL:2105648",
      "type": "Compound",
      "label": "Palovarotene",
      "properties": {
        "name": "PALOVAROTENE",
        "mechanism": "Retinoic acid receptor gamma agonist",
        "max_phase": 4,
        "iuphar_id": "IUPHAR:8276",
        "type": "Synthetic organic",
        "approved": true
      }
    },
    {
      "id": "CHEMBL:4298176",
      "type": "Compound",
      "label": "Garetosmab",
      "properties": {
        "name": "GARETOSMAB",
        "mechanism": "Inhibin beta A chain inhibitor",
        "max_phase": 3,
        "type": "Monoclonal antibody"
      }
    },
    {
      "id": "CHEMBL:217092",
      "type": "Compound",
      "label": "Saracatinib",
      "properties": {
        "name": "SARACATINIB",
        "mechanism": "Tyrosine-protein kinase SRC inhibitor",
        "max_phase": 2,
        "iuphar_id": "IUPHAR:7731",
        "type": "Synthetic organic",
        "approved": false
      }
    },
    {
      "id": "PubChem:CID60182388",
      "type": "Compound",
      "label": "LDN-212854",
      "properties": {
        "name": "LDN-212854",
        "synonyms": ["BMP Inhibitor III"],
        "molecular_formula": "C25H22N6",
        "chembl": "CHEMBL:2385591"
      }
    },
    {
      "id": "NCT:04307953",
      "type": "ClinicalTrial",
      "label": "Saracatinib FOP Trial",
      "properties": {
        "title": "Saracatinib Trial TO Prevent FOP",
        "status": "RECRUITING",
        "phase": null,
        "intervention": "AZD0530 Difumarate",
        "sponsor": "Amsterdam UMC",
        "start_date": "2020-08-05"
      }
    },
    {
      "id": "NCT:05039515",
      "type": "ClinicalTrial",
      "label": "Fidrisertib FOP Trial",
      "properties": {
        "title": "A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": null,
        "intervention": "IPN60130",
        "sponsor": "Clementia Pharmaceuticals Inc.",
        "start_date": "2021-12-01"
      }
    },
    {
      "id": "NCT:05394116",
      "type": "ClinicalTrial",
      "label": "Garetosmab FOP Trial",
      "properties": {
        "title": "Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": null,
        "sponsor": "Regeneron Pharmaceuticals",
        "start_date": "2022-11-21"
      }
    },
    {
      "id": "NCT:02279095",
      "type": "ClinicalTrial",
      "label": "Palovarotene Extension Trial",
      "properties": {
        "title": "A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARÎ³) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)",
        "status": "COMPLETED",
        "phase": null,
        "sponsor": "Clementia Pharmaceuticals Inc.",
        "start_date": "2014-10-09",
        "completion_date": "2022-09-20"
      }
    }
  ],
  "edges": [
    {
      "source": "HGNC:171",
      "target": "UniProtKB:Q04771",
      "type": "ENCODES",
      "properties": {}
    },
    {
      "source": "HGNC:171",
      "target": "MONDO:0007606",
      "type": "ASSOCIATED_WITH",
      "properties": {
        "score": 0.816,
        "evidence": "Open Targets associations"
      }
    },
    {
      "source": "STRING:9606.ENSP00000405004",
      "target": "STRING:9606.ENSP00000241416",
      "type": "INTERACTS",
      "properties": {
        "preferred_name_b": "ACVR2A",
        "score": 0.999,
        "evidence_sources": "database,textmining"
      }
    },
    {
      "source": "STRING:9606.ENSP00000405004",
      "target": "STRING:9606.ENSP00000340361",
      "type": "INTERACTS",
      "properties": {
        "preferred_name_b": "ACVR2B",
        "score": 0.998,
        "evidence_sources": "database,textmining"
      }
    },
    {
      "source": "STRING:9606.ENSP00000405004",
      "target": "STRING:9606.ENSP00000441954",
      "type": "INTERACTS",
      "properties": {
        "preferred_name_b": "SMAD5",
        "score": 0.835,
        "evidence_sources": "database,textmining"
      }
    },
    {
      "source": "STRING:9606.ENSP00000405004",
      "target": "STRING:9606.ENSP00000369154",
      "type": "INTERACTS",
      "properties": {
        "preferred_name_b": "SMAD9",
        "score": 0.888,
        "evidence_sources": "database,textmining"
      }
    },
    {
      "source": "STRING:9606.ENSP00000405004",
      "target": "STRING:9606.ENSP00000379204",
      "type": "INTERACTS",
      "properties": {
        "preferred_name_b": "BMP7",
        "score": 0.999,
        "evidence_sources": "experiments,database,textmining"
      }
    },
    {
      "source": "STRING:9606.ENSP00000405004",
      "target": "STRING:9606.ENSP00000463051",
      "type": "INTERACTS",
      "properties": {
        "preferred_name_b": "GDF2",
        "score": 0.998,
        "evidence_sources": "experiments,database,textmining"
      }
    },
    {
      "source": "CHEMBL:2105648",
      "target": "MONDO:0007606",
      "type": "TREATS",
      "properties": {
        "mechanism": "Retinoic acid receptor gamma agonist",
        "max_phase": 4
      }
    },
    {
      "source": "CHEMBL:4298176",
      "target": "MONDO:0007606",
      "type": "TREATS",
      "properties": {
        "mechanism": "Inhibin beta A chain inhibitor",
        "max_phase": 3
      }
    },
    {
      "source": "CHEMBL:217092",
      "target": "MONDO:0007606",
      "type": "TREATS",
      "properties": {
        "mechanism": "Tyrosine-protein kinase SRC inhibitor",
        "max_phase": 2
      }
    },
    {
      "source": "CHEMBL:2105648",
      "target": "NCT:02279095",
      "type": "TESTED_IN",
      "properties": {
        "status": "COMPLETED"
      }
    },
    {
      "source": "CHEMBL:4298176",
      "target": "NCT:05394116",
      "type": "TESTED_IN",
      "properties": {
        "status": "ACTIVE_NOT_RECRUITING"
      }
    },
    {
      "source": "CHEMBL:217092",
      "target": "NCT:04307953",
      "type": "TESTED_IN",
      "properties": {
        "status": "RECRUITING"
      }
    }
  ],
  "metadata": {
    "protocol": "Fuzzy-to-Fact",
    "phases_completed": [
      "ANCHOR",
      "ENRICH",
      "EXPAND",
      "TRAVERSE_DRUGS",
      "TRAVERSE_TRIALS",
      "VALIDATE",
      "PERSIST"
    ],
    "date": "2026-02-07",
    "data_sources": [
      "HGNC",
      "UniProt",
      "Open Targets",
      "STRING",
      "ChEMBL",
      "PubChem",
      "IUPHAR",
      "ClinicalTrials.gov"
    ],
    "notes": "FOP is a gain-of-function disease caused by ACVR1 mutations. ACVR1 agonists (Eptotermin Alfa, Dibotermin Alfa) were excluded as they would worsen the disease. Drugs targeting pathway inhibition or downstream modulation are the therapeutic focus."
  }
}
